RESEARCH PAPER
Examining retail purchases of cigarettes and nicotine replacement therapy in Finland
David S. Timberlake 1, 2  
,  
Terhi Kurko 3
,  
Arja H. Rimpelä 1, 4, 5
,  
 
 
More details
Hide details
1
Faculty of Social Sciences, Tampere University, Tampere, Finland
2
Program in Public Health, University of California, Irvine, United States
3
The Social Insurance Institute of Finland, Helsinki, Finland
4
PERLA - Tampere Centre for Childhood, Youth and Family Research, Tampere University, Tampere, Finland
5
Department of Adolescent Psychiatry, Tampere University Hospital, Tampere, Finland
CORRESPONDING AUTHOR
David S. Timberlake   

Program in Public Health, University of California, Anteater Instruction & Research Offices, Irvine, CA, United States
Publish date: 2019-05-03
 
Tob. Induc. Dis. 2019;17(May):39
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Finland’s success in achieving the goal of its tobacco endgame largely depends on rectifying deficiencies in the delivery of smoking cessation services. One such weakness, which has not been documented with empirical data, is misuse of nicotine replacement therapy (NRT). This study’s objective was to examine purchase patterns of NRT for estimating improper use of the medication. The study was based on the assumption that duration of a purchase episode is indicative of either proper use or misuse of NRT.

Methods:
The participants (n=728), who purchased at least one NRT product in 2016 (mostly gum/lozenge), were selected through enrollment in a large customer loyalty program in Finland (LoCard). Participants were categorized into one of five groups according to their longest purchase episode of NRT, defined by purchases made in consecutive, 4-week intervals.

Results:
Most participants, who did not adhere to NRT guidelines, either purchased the medication for too short (≤4 weeks, 63.5%) or too long (>24 weeks, 13.2%) of a purchase episode. Median purchases of NRT in the first month of use were one and four in the former and latter, respectively. In contrast to other groups, persistent users (>24 weeks) did not curtail purchases of NRT across several 4-week intervals, suggesting potential for dependence on NRT.

Conclusions:
The observation that most purchase episodes were terminated prematurely is consistent with surveys reporting widespread NRT misuse. Given uncertainty of greater regulation of NRT sales through legislation, it would be prudent for Finnish retailers to promote proper use of the therapy.

ACKNOWLEDGEMENTS
The authors thank the S Group for the use of retail purchases from members of the customer loyalty program. The primary author thanks the Fulbright Finland Foundation for providing salary and other resources which made this project possible. We thank three anonymous reviewers for their helpful suggestions.
CONFLICTS OF INTEREST
The authors declare that they have no competing interests, financial or otherwise, related to the current work. T. Kurko is a member of the working group appointed by the Finnish Medical Society Duodecim and the Finnish Association for General Practice of the Tobacco and Nicotine Dependency, Prevention and Treatment Current Care Guideline. The rest of the authors have also completed and submitted an ICMJE form for disclosure of potential conflicts of interest.
FUNDING
The study was supported by the Finland Fulbright Foundation.
AUTHORS' CONTRIBUTIONS
D.S.T., J.J. and J.N. formulated the hypothesis and analytical methodology. D.S.T. and J.J. coded the data and conducted the statistical analyses. T.K. and A.H.R. provided policy insight, guidance on clinical recommendations and patterns of N.R.T. use typically observed in practice. D.S.T. wrote most of the manuscript and J.J., T.K., A.H.R. and J.N. provided critical review and editing.
PROVENANCE AND PEER REVIEW
Not commissioned; externally peer reviewed.
 
REFERENCES (24)
1.
Shiffman S, Sweeney CT. Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability? Health Policy. 2008;86(1):17-26. doi:10.1016/j.healthpol.2007.08.006
 
2.
Shiffman S, Ferguson SG, Hellebusch SJ. Physicians' counseling of patients when prescribing nicotine replacement therapy. Addict Behav. 2007;32(4):728-739. doi:10.1016/j.addbeh.2006.06.021
 
3.
Solberg LI, Asche SE, Boyle RG, Boucher JL, Pronk NP. Frequency of physician-directed assistance for smoking cessation in patients receiving cessation medications. Arch Intern Med. 2005;165(6):656-660. doi:10.1001/archinte.165.6.656
 
4.
Kurko T, Linden K, Vasama M, Pietila K, Airaksinen M. Nicotine replacement therapy practices in Finland one year after deregulation of the product sales--has anything changed from the community pharmacy perspective? Health Policy. 2009;91(3):277-285. doi:10.1016/j.healthpol.2008.12.013
 
5.
Aalto-Setala V, Alaranta A. Effect of deregulation on the prices of nicotine replacement therapy products in Finland. Health Policy. 2008;86(2-3):355-362. doi:10.1016/j.healthpol.2007.11.013
 
6.
Kurko T. Deregulation of Nicotine Replacement Therapy Products in Finland: Reason for Pharmaceutical Policy Changes and Reflections on Smoking Cessation Practices. Finland: University of Helsinki; 2005.
 
7.
National Agency of Medicines and Social Insurance Institution. Sales of nicotine replacement therapy products. Helsinki, Finland: F.S.o. Medicines; 2007.
 
8.
Shiffman S, Hughes JR, Di Marino ME, Sweeney CT. Patterns of over-the-counter nicotine gum use: persistent use and concurrent smoking. Addiction. 2003;98(12):1747-1753. doi:10.1111/j.1360-0443.2003.00575.x
 
9.
Shiffman S, Hughes JR, Pillitteri JL, Burton SL. Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample. Tob Control. 2003;12(3):310-316. doi:10.1136/tc.12.3.310
 
10.
Fucito LM, Bars MP, Forray A, Rojewski AM, Shiffman S, Selby P, West R, Foulds J, Toll BA, Writing Committee for the SRNT Policy and Treatment Networks. Addressing the evidence for FDA nicotine replacement therapy label changes: a policy statement of the Association for the Treatment of Tobacco use and Dependence and the Society for Research on Nicotine and Tobacco. Nicotine Tob Res. 2014;16(7):909-914. doi:10.1093/ntr/ntu087
 
11.
Zapawa LM, Hughes JR, Benowitz NL, Rigotti NA, Shiffman S. Cautions and warnings on the US OTC label for nicotine replacement: what's a doctor to do? Addict Behav. 2011;36(4):327-332. doi:10.1016/j.addbeh.2010.12.003
 
12.
Zhang B, Cohen JE, Bondy SJ, Selby P. Duration of nicotine replacement therapy use and smoking cessation: a population-based longitudinal study. Am J Epidemiol. 2015;181(7):513-520. doi:10.1093/aje/kwu292
 
13.
Balmford J, Borland R, Hammond D, KM Cummings. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res. 2011;13(2):94-102. doi:10.1093/ntr/ntq215
 
14.
Ministry of Social Affairs and Health. Roadmap to a Tobacco-Free Finland: Action Plan on Tobacco Control. Helsinki, Finland: Ministry of Social Affairs and Health; 2014.
 
15.
Joossens L, Raw M. The Tobacco Control Scale 2016 in Europe. Belgium, Brussels: A.o.E.C. Leagues; 2017.
 
16.
Nevalainen J, Erkkola M, Saarijarvi H, Nappila T, Fogelholm M. Large-scale loyalty card data in health research. Digit Health. 2018;4. doi:10.1177/2055207618816898
 
17.
Preliminary and unpublished data from the LoCard data collection for 2016-2018, 2019.
 
18.
Raupach T, Brown J, Herbec A, Brose L, West R. A systematic review of studies assessing the association between adherence to smoking cessation medication and treatment success. Addiction. 2014;109(1):35-43. doi:10.1111/add.12319
 
19.
Burns EK, Levinson AH. Discontinuation of nicotine replacement therapy among smoking-cessation attempters. Am J Prev Med. 2008;34(3):212-215. doi:10.1016/j.amepre.2007.11.010
 
20.
Kurko T, Linden K, Kolstela M, Pietila K, Airaksinen M. Is nicotine replacement therapy overvalued in smoking cessation? Analysis of smokers' and quitters' communication in social media. Health Expect. 2015;18(6):2962-2977. doi:10.1111/hex.12280
 
21.
Bansal MA, Cummings KM, Hyland A, Giovino GA. Stop-smoking medications: who uses them, who misuses them, and who is misinformed about them? Nicotine Tob Res. 2004;6(Suppl 3):S303-310. doi:10.1080/14622200412331320707
 
22.
Royal College of Physicians. Harm reduction in nicotine addiction: Helping people who can't quit. London, England: Royal College of Physicians; 2007.
 
23.
Hughes JR, Pillitteri JL, Callas PW, Callahan R, Kenny M. Misuse of and dependence on over-the-counter nicotine gum in a volunteer sample. Nicotine Tob Res. 2004;6(1):79-84. doi:10.1080/14622200310001656894
 
24.
Ministry of Social Affairs and Health: Smoke-free Finland through better tobacco and nicotine policy. https://stm.fi/artikkeli/-/ass.... Accessed May 31, 2018.
 
eISSN:1617-9625